The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company
CureVac (NASDAQ: CVAC) recently started its phase study IIa in Peru and Panama. Around 700 people are taking part in it. The study aims to find suitable dosages for the vaccine. To this end, test persons are vaccinated twice within 28 days. Other competitors, such as BioNTech, are already testing their vaccine on more volunteers. BioNTech recently started its phase III study in South Africa and is testing the vaccine on more than 40,000 people worldwide.
CureVac and BioNTech: There will be losers
That the race for a vaccine is fierce is also shown by the share prices.
All vaccine shares received advanced praise in the first half of the year, and some shares rose significantly. However, CureVac has been running into sand for a few days now - the stock lost around 4% within five days. Although the share price development is of little relevance, as the Company only went public during the pandemic and is therefore ambitiously valued, there are increasing signs of weakness.
The
BioNTech (NASDAQ: BNTX) share has not got off the ground lately. This performance may be bearable given the 540% increase in value within one year, but investors are rightly asking themselves how things will continue with vaccination shares.
The foreign competition seems to have managed - also thanks to laxer approval procedures - to overtake German companies. According to Russia, it has already developed a second vaccine. The Chinese supplier Sinopharm now offers students an experimental vaccine free of charge. Almost 500,000 test persons have already been vaccinated. The measures aim to increase confidence in the vaccine.
There will be several vaccines in the future, and the preparations from Russia and China, which are being fast-tracked, will not render competition for established biotech companies in Europe and the USA. There will also be losers in the race for the best vaccines,
especially for stocks like CureVac and also BioNTech, as the drop could be from a high level. For investors, it may make sense to step out of the race for the vaccine and think about alternatives.
A healthy immune system not only helps with Covid-19
The pandemic proves that a functioning immune system can not only make the difference between life and death in the worst-case scenario but also helps to ward off diseases completely. The Canadian Company
Valeo Pharma (CSE: VPH) is focused on the commercialization of Hesperco™, a dietary supplement containing a highly effective antioxidant intended to support the immune system.
It was approved by the Canadian authorities a few weeks ago, and three days ago, Valeo Pharma announced that it had begun shipping the product. The capsules will be available at all major retailers in Canada in early November.
Valeo Pharma is at the beginning of its investment story
Valeo Pharma is working with Ingenew Pharma in the development, production, and distribution of the new dietary supplement, which provides all the necessary scientific data on the new product. In addition to Hesperco™, Valeo Pharma offers prescription drugs and focuses on neurodegenerative diseases, oncological products, and special hospital needs. Although Valeo Pharma's share price has also recently had to give up its feathers, the Company is still at the beginning of its investment story.
The small Canadian Company has not yet received any advance praise from the market, such as CureVac or BioNTech. Nevertheless, the stock could benefit indirectly from the pandemic.
CONFLICT OF INTEREST & RISK NOTE
We would like to point out that Apaton Finance GmbH, the owner of news.financial, as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our ´
Conflict of Interest & Risk Disclosure´.